Last reviewed · How we verify
MitoQ Compound
At a glance
| Generic name | MitoQ Compound |
|---|---|
| Sponsor | Imperial College London |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- ROAR-DIGAP: A Widely Inclusive, Largely Virtual Pilot Trial Utilizing DIGAP (Deep Integrated Genomics Analysis Platform) To Personalize Treatments (PHASE2)
- Examining the Effects of Mitochondrial Oxidative Stress in DCM (PHASE2)
- Long-term COVID and Rehabilitation (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MitoQ Compound CI brief — competitive landscape report
- MitoQ Compound updates RSS · CI watch RSS
- Imperial College London portfolio CI